Form D · Biotechnology
A5 Laboratories Inc.
Lachine, A8 · CIK 0001381054
Offering snapshot reported Mar 11, 2011 · SEC filing
- Reported sold
- $545K Offering amount: $2.55M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $200K Reported outside-investor minimum
- First sale
- Feb 23, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 11, 2011 | Initial | $545,000 | No comparison | 1 | SEC filing |
| Nov 13, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $22.8K
- Finders' fees
- $0
- Form D file number
- 021-156543
Total amount sold includes an OID of approximately 9.63% of the total offering amount and a $15,000 payment to cover Investor expenses. Actual funding consisted of (i) $285,000 in cash and (ii) 10 convertible notes in the aggregate amount of $2,000,000.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| MidSouth Capital, Inc. | 35039 |
Source: Form D, filed Mar 11, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Azani | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10300 Chemin Cote De Liesse
Lachine, A8, H8T1A3
Lachine, A8, H8T1A3